Financial Performance - Invivyd, Inc. reported Q4 2025 revenue of $17.2 million, surpassing estimates of $15.5 million, indicating strong demand for PEMGARDA [2][5] - The revenue of $17.2 million represents a 25% increase year-over-year and a 31% increase quarter-over-quarter [2] - The company reported an earnings per share (EPS) of -$0.064, slightly below the estimated EPS of -$0.06 [1] Cash Position - By the end of 2025, Invivyd had cash and cash equivalents totaling $226.7 million, supported by over $200 million raised through financing transactions in the latter half of the year [2][5] - The company maintains a strong equity position with a debt-to-equity ratio of 0.010 and a robust current ratio of 7.24 [4] Clinical Development - Invivyd is advancing its DECLARATION Phase 3 pivotal clinical trial for VYD2311, a vaccine-alternative antibody aimed at preventing COVID-19 [3][5] - The trial has received Fast Track designation from the FDA, with top-line data expected by mid-2026 [3] - The trial has reached full enrollment, and the Independent Data Monitoring Committee (IDMC) has recommended the inclusion of pregnant and breastfeeding women [3] Valuation Metrics - The company has a price-to-earnings (P/E) ratio of approximately -5.61, indicating negative earnings [4] - Its price-to-sales ratio is about 4.25, suggesting investors are willing to pay $4.25 for every dollar of sales [4] - The enterprise value to sales ratio is low at 0.052, which may imply undervaluation relative to its sales [4]

Core Insights - Invivyd, Inc. reported strong financial results for Q4 and full year 2025, with significant revenue growth and reduced operating expenses, highlighting the potential commercialization of VYD2311 and ongoing clinical trials [2][4][12]. Financial Performance - Q4 2025 net product revenue from PEMGARDA reached $17.2 million, a 25% increase year-over-year and a 31% increase quarter-over-quarter [4][12]. - Full year 2025 net product revenue totaled $53.4 million, compared to $25.4 million in 2024 [12]. - Cash and cash equivalents at year-end 2025 were $226.7 million, bolstered by over $200 million raised in financing during the second half of 2025 [4][12]. - Research and Development (R&D) expenses decreased to $38.3 million in 2025 from $137.3 million in 2024, primarily due to lower contract research costs [12]. - Selling, General & Administrative (SG&A) expenses increased to $66.9 million in 2025 from $63.4 million in 2024, attributed to higher personnel-related costs [12]. - The net loss for 2025 was $52.5 million, significantly reduced from $169.9 million in 2024, with a net loss per share of $0.30 compared to $1.43 in the previous year [12][36]. Clinical and Regulatory Developments - The DECLARATION Phase 3 pivotal clinical trial for VYD2311 has achieved full enrollment, with top-line data expected in mid-2026 [4][5]. - The FDA granted Fast Track designation for VYD2311 in December 2025, facilitating expedited development and review processes [5][7]. - The Independent Data Monitoring Committee (IDMC) recommended allowing pregnant and breastfeeding women to enroll in the DECLARATION trial after reviewing unblinded safety data [5]. - The LIBERTY Phase 3 clinical trial will assess the safety and immunologic profile of VYD2311 compared to mRNA COVID vaccines, with specific monitoring for adverse events of interest [5][7]. Pipeline Expansion - Invivyd is advancing its pipeline with VBY329, a monoclonal antibody candidate for the prevention of Respiratory Syncytial Virus (RSV) in children, expected to enter IND readiness in the second half of 2026 [7][12]. - The company is also planning a Phase 2 clinical trial for VYD2311 in individuals with Long COVID or COVID vaccine injury, anticipated to start by mid-2026 [7]. Corporate Updates - Michael Mina, M.D., Ph.D., has been appointed as Chief Medical Officer, indicating a strategic move to enhance clinical leadership [12]. - Invivyd is launching a national multimedia educational campaign in partnership with Lindsey Vonn to raise public awareness about the role of antibodies in disease prevention [12].

Core Viewpoint - Invivyd, Inc. and the SPEAR Study Group are set to initiate a Phase 2 clinical trial for the monoclonal antibody VYD2311, targeting individuals suffering from Long COVID or COVID vaccine injury, addressing a significant unmet medical need in the U.S. [1][2] Group 1: Clinical Trial Details - The Phase 2 clinical trial is expected to start by mid-2026 and will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in individuals with Long COVID or COVID vaccine injury [4][5] - Participants will include those with Long COVID showing evidence of chronic infection or antigen persistence, as well as individuals injured by COVID vaccines [4] - The trial design includes administering multiple high doses of VYD2311 over the long term to assess safety and potential clinical benefits compared to a placebo [4][5] Group 2: Scientific Rationale - Data indicates that prolonged presence of spike protein antigen may contribute to ongoing morbidity in individuals with Long COVID and those experiencing chronic conditions post-vaccination [2] - The SPEAR Study Group was formed to advance understanding of Long COVID and explore potential therapeutic options, with Invivyd's monoclonal antibodies seen as promising candidates [2][3] Group 3: Product Information - VYD2311 is a novel monoclonal antibody candidate developed to address the urgent need for new therapeutic options for COVID-19, demonstrating in vitro antiviral activity against all clinically recorded variants of SARS-CoV-2 [6][7] - The antibody was engineered using Invivyd's proprietary technology platform, optimized for neutralizing contemporary virus lineages [7] - VYD2311 aims to deliver clinically meaningful titer levels through more patient-friendly administration methods, such as intramuscular injection [6]

Group 1 - Invivyd, Inc. reported preliminary fourth-quarter 2025 net product revenue of $17.2 million from PEMGARDA, reflecting a 25% year-over-year growth and a 31% increase from the previous quarter [1][2] - The company ended 2025 with $226.7 million in cash and equivalents, supported by financing completed in the second half of the year, and has a current ratio of 2.47, indicating strong liquidity for operations and pipeline advancement [1][3] - Invivyd has launched the DECLARATION Phase 3 pivotal trial for VYD2311, a monoclonal antibody for COVID-19 prevention, which received FDA Fast Track designation in December 2025, with top-line results expected by mid-2026 [2][3] Group 2 - The company is expanding its pipeline beyond COVID-19, with VBY329, an RSV antibody candidate expected to reach IND readiness in late 2026, and a measles antibody program in preclinical development with candidate selection planned for early 2026 [3][4] - PEMGARDA has a gross margin of 93.3%, highlighting its commercial potential in the market [2]

Core Insights - Invivyd, Inc. reported strong financial results for Q3 2025, with a net product revenue of $13.1 million, reflecting a 41% year-over-year growth and an 11% quarter-over-quarter growth [5][10] - The company is preparing for pivotal studies and a potential commercial launch of VYD2311, an antibody alternative to COVID vaccination, following recent IND clearance and FDA alignment [2][4] - Invivyd's cash position improved significantly, ending Q3 2025 with $85 million in cash and cash equivalents, bolstered by a public offering and ATM facility [5][10] Recent Business Highlights - The company is focused on the urgent need for antibody protection against COVID-19 and is also exploring additional pathogens beyond COVID [2][3] - The REVOLUTION clinical program for VYD2311 includes two pivotal trials: DECLARATION and LIBERTY, expected to begin around year-end 2025, with top-line data anticipated by mid-2026 [5][6][7] Clinical & Regulatory Developments - Invivyd received U.S. IND clearance for VYD2311, which is designed to prevent COVID-19, and is preparing for the initiation of the DECLARATION and LIBERTY clinical trials [5][6] - The DECLARATION trial will evaluate the safety and efficacy of VYD2311 in preventing symptomatic COVID-19, while the LIBERTY trial will assess its interaction with mRNA-based COVID vaccines [6][7] Commercial Execution - The uptake of PEMGARDA (pemivibart) continues to grow among healthcare providers, supported by Invivyd's sales force [6] - Positive in vitro neutralization data for PEMGARDA and VYD2311 against the XFG variant of SARS-CoV-2 was announced, indicating no significant change in neutralization activity [6][8] Corporate and Financial Updates - The company reported a net loss of $10.5 million for Q3 2025, a significant reduction from a net loss of $60.7 million in Q3 2024 [10][27] - Research and development expenses decreased to $8 million in Q3 2025 from $57.9 million in the same period of 2024, primarily due to reduced clinical trial costs [10][27] Pipeline Expansion - Invivyd is initiating discovery efforts to expand its pipeline beyond SARS-CoV-2, targeting potential pathogens such as respiratory syncytial virus (RSV) and measles [8][9]

Core Insights - Invivyd, Inc. announced positive in vitro neutralization data for PEMGARDA (pemivibart) against the XFG variant of SARS-CoV-2, indicating no significant change in neutralization activity [1][2][3] - The company anticipates continued clinical activity for pemivibart as the targeted epitopes remain structurally intact across various SARS-CoV-2 variants [2][3] - Invivyd is advancing its next-generation monoclonal antibody candidate, VYD2311, which has shown similar neutralization results with higher potency [3][12] Company Developments - PEMGARDA is authorized by the FDA for pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients, demonstrating consistent in vitro neutralizing activity over several years [1][4][7] - The company plans to provide updated data on PEMGARDA's neutralizing activity to the FDA, which will be included in the PEMGARDA Fact Sheet for Healthcare Providers [4][5] - VYD2311 is designed to offer a more patient-friendly administration route and aims to address the urgent need for new COVID-19 prophylactic and therapeutic options [12][13] Industry Context - COVID-19 activity is reportedly on the rise in the U.S., with high levels of viral activity detected in wastewater across 12 states, and infections growing in 34 states [2][3] - The CDC's data indicates that the XFG variant is contributing to a growing wave of COVID-19 cases in America, reinforcing the need for effective treatments like PEMGARDA and VYD2311 [5][6] - The stability of the epitopes targeted by Invivyd's monoclonal antibodies across SARS-CoV-2 evolution highlights the company's robust molecular design strategy [3][4]

Core Insights - Invivyd, Inc. is entering a transformative phase with a focus on VYD2311 as a promising alternative to COVID-19 vaccination, supported by recent clinical trial data [2][5][7] - The company reported a significant year-over-year increase in net product revenue for PEMGARDA, reaching $11.8 million in Q2 2025, representing a 413% growth [5][9] - Despite not meeting the near-term profitability target for the first half of 2025, Invivyd remains optimistic about achieving profitability with the upcoming respiratory virus season [5][9] Recent Business Highlights - The company is actively designing clinical and go-to-market strategies for VYD2311, which has shown an attractive safety profile and pharmacokinetics in Phase 1/2 trials [2][5] - Invivyd anticipates identifying a best-in-class RSV candidate in Q3 2025 and a preclinical measles candidate by the end of 2025 [2][5] Clinical & Regulatory Developments - Invivyd has aligned with the U.S. FDA on a rapid pathway to full approval for VYD2311, which aims to protect American adults and adolescents from COVID-19 [5][7] - The VYD2311 candidate demonstrated a 76-day observed half-life for intramuscular administration, indicating potential for long-term protection [5][6] Commercial Execution - PEMGARDA's uptake is increasing among healthcare providers for immunocompromised patients, supported by Invivyd's sales force and expanded field presence [6][10] - The product has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for B-Cell Lymphomas [6] Financial Results - For Q2 2025, Invivyd reported a net loss of $14.7 million, a decrease from $47.2 million in Q2 2024, with a net loss per share of $0.12 [9][28] - Research and development expenses were $9.6 million for the quarter, down from $30.3 million in the same period of 2024, primarily due to reduced clinical trial costs [9][28] Pipeline Expansion - The company is exploring pipeline expansion beyond SARS-CoV-2, including potential targets like RSV and measles [11][19] - Invivyd has formed the SPEAR Study Group to assess monoclonal antibody therapy effects for Long COVID and COVID-19 Post-Vaccination Syndrome [11][19]

Core Viewpoint - Invivyd, Inc. has received guidance from the U.S. FDA on a rapid pathway for Biologics License Application (BLA) approval for its monoclonal antibody candidate VYD2311, aimed at preventing COVID-19, which could provide an alternative to vaccines for the American population [1][2][3] Group 1: FDA Guidance and Clinical Trials - The FDA advised that a single Phase 2/3 randomized, double-blind, placebo-controlled trial could support a BLA submission for VYD2311, focusing on symptomatic COVID-19 events [1][3] - Invivyd plans to study two doses of VYD2311 to evaluate differences in protection levels and safety, aiming to provide more options for COVID-19 protection [2][4] - The primary endpoint for the trial is RT-PCR-confirmed symptomatic COVID-19, with a measurement timepoint expected at 12 weeks, and a potential longer duration of 24 weeks [3][4] Group 2: Product Profile and Market Position - VYD2311 is designed to be a low-dose, intramuscular, scalable, and cost-effective option for adults and adolescents, with potential expansion to pediatric populations [4][5] - The antibody is engineered to neutralize contemporary virus lineages and is based on a common molecular lineage with other successful Invivyd antibodies [2][8] - Invivyd's analysis suggests that VYD2311 may provide robust, long-term protection from symptomatic COVID-19 due to its high potency and long half-life of approximately 76 days [4][5] Group 3: Strategic Importance and Future Plans - The company emphasizes the importance of providing a non-vaccine choice for COVID-19 prevention amidst declining public trust in vaccines [2][3] - Invivyd has quantities of VYD2311 available for clinical supply and potential commercial launch, indicating readiness for market introduction if approved [6][8] - The company aims to finalize a pivotal clinical trial design with the FDA and is committed to advancing innovative solutions for COVID-19 prevention [6][3]

Core Insights - Invivyd, Inc. announced full Phase 1/2 clinical data for VYD2311, a next-generation monoclonal antibody (mAb) candidate aimed at preventing and treating COVID-19 [1] - VYD2311 is structurally 99%+ identical to previous antibodies and is designed to enhance potency and resistance against SARS-CoV-2 variants [2][10] - The Phase 1/2 study demonstrated that VYD2311 was well tolerated with mild to moderate adverse events and a long half-life, suggesting potential for long-term protection [4][5] Company Overview - Invivyd, Inc. is focused on developing innovative monoclonal antibodies to combat serious viral infectious diseases, starting with SARS-CoV-2 [18] - The company utilizes a proprietary technology platform to create antibodies that can adapt to viral evolution [18] Clinical Trial Details - The Phase 1/2 study involved 40 subjects and tested various routes of administration (IV, IM, SC) and doses to maximize flexibility for future registrational pathways [3] - VYD2311 showed a half-life ranging from 61 days (IV) to 76 days (IM), significantly longer than pemivibart's 49 days [5] Safety and Efficacy - All adverse events reported were mild to moderate, with no serious adverse events linked to the study drug [4] - The modeling analysis indicated that VYD2311 could provide robust protection against symptomatic COVID-19, potentially surpassing vaccine efficacy [8][10] Regulatory Plans - Invivyd plans to engage with the FDA in early Q3 2025 to discuss registration pathways for VYD2311 and subsequent COVID-19 mAbs [6][8] - The company aims to provide non-vaccine mediated protection for vulnerable populations, including the elderly and immunocompromised individuals [8][10]

Core Insights - Invivyd, Inc. announced the publication of results from its CANOPY Phase 3 clinical trial of pemivibart, demonstrating its safety and efficacy for the prevention of symptomatic COVID-19 in a contemporary U.S. population facing immune-evasive Omicron variants [1][4][6] Group 1: Clinical Trial Overview - The CANOPY Phase 3 clinical trial randomized 788 adult participants across 18 sites, focusing on immunocompromised individuals and those at risk due to regular face-to-face interactions [2][8] - The trial met all primary and exploratory endpoints during a significant COVID-19 transmission period in the U.S. from September 2023 to September 2024 [2][8] - Pemivibart showed an 84% relative risk reduction in symptomatic COVID-19 compared to placebo over six months [4][6] Group 2: Safety and Tolerability - Pemivibart was generally well-tolerated, with most adverse events classified as mild to moderate [3][6] - The most common treatment-emergent adverse events included infusion-related reactions, with a low incidence of anaphylactic reactions (0.6%) [3][12] - The safety profile aligns with previous clinical trials for COVID-19 monoclonal antibodies [3][6] Group 3: Regulatory and Future Implications - The trial's results support the emergency use authorization (EUA) of PEMGARDA (pemivibart) for pre-exposure prophylaxis in certain immunocompromised patients [2][10] - The publication aims to educate clinicians on the potential of monoclonal antibodies in combating COVID-19, particularly for immunocompromised individuals [5][7] - Invivyd plans to leverage data from the CANOPY trial to expedite the approval of novel antibodies like VYD2311 [7][18]